BrandWikiReturn

Otsuka Pharmaceutical

Otsuka Pharmaceutical Co., Ltd. (大塚製薬株式会社), abbreviated OPC, is a pharmaceutical company headquartered in Chiyoda, Tokyo. The company was established on August 10, 1964.

History

OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering (IPO) on December 15, 2010, at which time Otsuka Holdings was Japan's No. 2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.[1]

Otsuka Pharmaceutical Co. Ltd Holdings

In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.[2]

In 1988, Otsuka aquired Pharmavite, the California-based manufacturer of Nature Made, MegaFood, and other brands of vitamins and nutritional supplements.[3]

In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.[4]

In early 2012, Otsuka announced it would focus its "future operations on CNS disorders and oncology".[5] This decision necessitated a revision in the terms of an agreement with UCB to end collaboration on immunology products while continuing collaboration in the CNS area.[6]

In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm's Phase III-ready ADHD drug centanafadine (previously EB-1020). Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.[7]

In late 2023, the company announced the acquisition of Mindset Pharma for $58.6 million.[8]

In March 2026, Otsuka Pharmaceutical acquired Transcend Therapeutics and its drug candidate methylone (TSND-201).[9]

Acquisition history

  • Otsuka Pharmaceutical Co., Ltd
  • Ridge Vineyards (Acq 1986) [10]
  • Crystal Geyser Water Company (Acq 1990) [11]
  • Astex Pharmaceuticals (Merged 2011, Acq 2013) [12]
  • Astex Therapeutics Limited
  • SuperGen, Inc
  • Avanir Pharmaceuticals (Acq 2014) [13]
  • Daiya (Acq 2017) [14]
  • ReCor Medical, Inc. (Acq 2019) [15]
  • Otsuka America, Inc
  • Visterra (Acq 2019) [16]
  • Neurovance, Inc (Acq 2017) [17]
  • Mindset Pharma Inc (Acq 2023)
  • Jnana Therapeutics Inc. (Acq 2024) [18]

Products

Pharmaceutical

  • Aripiprazole / Abilify[19][20]
  • Brexpiprazole / Rexulti
  • Rejoyn

Nutraceutical

  • CalorieMate
  • Pocari Sweat
  • Oronamin C
  • SoyJoy
  • Amino-Value[21]

Facilities

External links

References

  1. Junko Fujita, Antoni Slodkowski. Otsuka up 5 pct in Tokyo debut after $2.4 bln IPO-UPDATE 1 December 16, 2010, retrieved January 15, 2012^
  2. Tokushima Vortis 15 January 2020, retrieved October 30, 2020^
  3. Japanese pharmecutical giant acquires U.S. vitamin maker. LOS ANGELES (UPI)... - UPI Archives UPI, retrieved 2026-04-06^
  4. Otsuka Pharmaceutical Co., Ltd. invests in French leading mineral water company, ALMA S.A. otsuka.co.jp, May 28, 2008, retrieved October 30, 2020^
  5. Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead BioSpace, January 13, 2012, retrieved January 15, 2012^
  6. UCB and Otsuka to focus collaboration on CNS disorders Zenopa, January 13, 2012, retrieved January 15, 2012^
  7. Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN GEN, 3 March 2017, retrieved 23 April 2018^
  8. Laura Howes. Otsuka to buy Mindset Pharma Chemical & Engineering News, September 9, 2023, retrieved June 1, 2024^
  9. Will Maddox. Otsuka buys Transcend in $1.2B deal, nabbing MDMA analog for psychiatric conditions Fierce Biotech, 27 March 2026, retrieved 14 April 2026^
  10. Paul Draper Winemaker, Ridge Vineyards, CEO Part 1 | Otsuka People Talk^
  11. Otsuka.com Library, Otsuka Pharmaceutical. Retrieved September 21, 2019.^
  12. Tim Kelly. Japan's Otsuka to buy U.S. cancer firm Astex for $886 million Reuters, September 5, 2013^
  13. Jonathan Soble. Otsuka of Japan to Buy Avanir Pharmaceuticals for $3.5 Billion The New York Times, 2 December 2014, retrieved 23 April 2018^
  14. Plant-based food firm Daiya bought for $325.97M by pharma company Otsuka Food Dive^
  15. Otsuka Medical Devices, Otsuka Holdings and ReCor Medical Announce Signing of Merger Agreement BioSpace, retrieved 2020-10-29^
  16. Otsuka to Acquire Visterra for $430M, Adding to Its Pipeline and Platforms July 11, 2018^
  17. Otsuka to Buy Neurovance for up to $250M to Acquire Phase III-Ready ADHD Drug - GEN GEN, 3 March 2017, retrieved 23 April 2018^
  18. Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc. GEN, 23 September 2024, retrieved 2 October 2024^
  19. Aripiprazole AdisInsight, retrieved 4 June 2017^
  20. Prakash B. Behere, Anweshak Das, Aniruddh P. Behere. Clinical Psychopharmacology: An Update Springer, 2018^
  21. Amino-Value Otsuka Pharmaceutical Co,. Ltd., retrieved 25 Feb 2026^
  22. 高崎工場 Otsuka Pharmaceutical Co,. Ltd., retrieved 25 Feb 2026^
  23. 袋井工場 Otsuka Pharmaceutical Co,. Ltd., retrieved 25 Feb 2026^
  24. 佐賀工場 Otsuka Pharmaceutical Co,. Ltd., retrieved 25 Feb 2026^
  25. 徳島工場エリア Otsuka Pharmaceutical Co,. Ltd., retrieved 25 Feb 2026^
  26. 徳島板野工場 Otsuka Pharmaceutical Co,. Ltd., retrieved 25 Feb 2026^
  27. 徳島ワジキ工場 Otsuka Pharmaceutical Co,. Ltd., retrieved 25 Feb 2026^